Clinical Report: Genomic and Phenotypic Approaches to Tailored Pharmacotherapy for Obesity
Overview
This comprehensive review synthesizes evidence on the variability of pharmacotherapy responses in obesity, emphasizing the role of phenotypic and genomic determinants.
Background
Obesity is a complex, chronic disease with significant interindividual variability in response to treatments. The effectiveness of anti-obesity medications is often limited by factors such as gastrointestinal intolerance and weight regain after treatment discontinuation, as noted in various studies.
Data Highlights
No numerical or trial data presented.
Key Findings
Obesity is characterized by significant interindividual variability in response to anti-obesity medications.
Early on-treatment weight change is a clinically actionable predictor of longer-term outcomes.
Phenotype-guided approaches can classify mechanisms affecting weight loss, such as impaired satiation and emotional eating.
Genomic signals related to obesity pharmacotherapy are promising but not yet ready for routine clinical application.
Weight regain after treatment discontinuation highlights the chronic nature of obesity management.
Clinical Implications
Clinicians should consider phenotype-guided treatment strategies and monitor early responses to optimize pharmacotherapy for obesity.
Conclusion
The review discusses the integration of phenotypic assessments and early monitoring in obesity pharmacotherapy.
by Dario S. Lopez Delgado, Miriam Gabriela Reyes-Zermeño, Elian David Sanjuanelo Lemus, Catherine G. Acosta-Celis, María Amparo Kantún-Marín, Martín Gomez-Lujan, Kevin Gabriel Fallaza-Moya, Oscar Muñoz-Chuquilín, Sandra Trujillo-Levano, Giancarlo Gutierrez-Chavez, Cesar Bonilla-Asalde, Oriana Rivera-Lozada, Joshuan J. Barboza
